
Open Your Free Demat Account
Enjoy low brokerage on delivery trades
BAJAJ BROKING
GlaxoSmithKline Pharmaceuticals Ltd. secured an income tax refund of ₹222.23 crore for FY 2022-23. The company reported a 37.8% YoY profit increase to ₹182.3 crore and a 60.1% EBITDA surge, driven by strong brand performance.
GlaxoSmithKline Pharmaceuticals Ltd. (GSK Pharma), a leading player in the global healthcare industry, announced on Tuesday, September 3, that it has received an income tax refund of ₹222.23 crore for the assessment year 2022-23. The refund follows an order issued by the Income Tax Department under Section 143(3), which pertains to scrutiny assessments. The news was shared in a regulatory filing with the stock exchanges.
The announcement of the tax refund comes on the heels of a strong financial performance by GSK Pharma in the first quarter of the fiscal year 2024. The company reported a notable 37.8% year-on-year (YoY) increase in net profit, amounting to ₹182.3 crore. This marks a significant rise from the ₹132.3 crore profit reported in the same quarter of the previous fiscal year.
The company's revenue also showed positive momentum, growing by 7% to ₹814.7 crore, compared to ₹761.7 crore in the corresponding period of the preceding fiscal. This growth was supported by robust sales from key brands, including Calpol, Augmentin, and T-Bact, which continued to gain market share.
At the operating level, GSK Pharma's earnings before interest, tax, depreciation, and amortisation (EBITDA) surged by 60.1%, reaching ₹230.6 crore in the first quarter of the current fiscal year. This is a substantial increase from the ₹144 crore reported in the corresponding quarter of the previous fiscal year. The company's EBITDA margin also improved significantly, standing at 28.3% in the reporting quarter, up from 18.9% in the previous year's corresponding period.
The growth in EBITDA and the expansion of margins highlight the company's operational efficiency and its ability to capitalise on market opportunities.
GSK Pharma's continued success can be attributed to the strong performance of its key brands. Calpol, Augmentin, and T-Bact, among others, contributed to a 10% growth in sales. Additionally, the company's respiratory portfolio, including products like Nucala and Trelegy, achieved an impressive 57% growth, further expanding access to critical treatments for patients.
The receipt of the ₹222.23 crore income tax refund, coupled with the robust financial results for the first quarter of FY 2024, underscores GSK Pharma's strong market position and economic health. The company's focus on expanding its key brands and improving operational efficiency continues to drive its growth trajectory.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading